Back to results
US 11,229,627 B1Granted
Opioid receptor modulator dosage formulations
AssigneeAllergan Holdings Unlimited Company
InventorsTim Costello, Jens Jozef Ceulemans, Eugeen Maria Jozef Jans, Philip Erna H. Heyns
Life of this patent
Estimating the term…
Abstract
Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Claims30
A pharmaceutical tablet comprising:
- about 75 mg or about 100 mg of 5-({[(2S)-2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid;
- about 70-90% by weight of a combination of a first filler and a second filler;
- about 3-7% by weight disintegrant;
- about 0.55-0.95% by weight colloidal silicon dioxide;
- and
- about 0.45-1% by weight lubricant;
- wherein the first filler is mannitol;
- and wherein the tablet comprises at least 10% by weight mannitol.
5 more elements
A pharmaceutical tablet comprising:
- about 75 mg or about 100 mg of 5-({[(2S)-2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid;
- about 60-80% by weight filler;
- about 7.5-12.5% by weight mannitol;
- about 3-7% by weight disintegrant;
- colloidal silicon dioxide;
- and
- about 0.45-1% by weight magnesium stearate.
4 more elements
Dependencies are inferred from the claim text.